GeneDx stock holds steady despite fraud allegations
GeneDx (NASDAQ:WGS) shares maintained their ground following a reiteration of a Hold rating and a $75.00 price target by Jefferies analysts. According to InvestingPro data, analyst targets for the ...
BTIG maintains GeneDx stock Buy rating, $95 target amid fraud claim
BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...
GeneDx selloff after short report ‘appears overdone,’ says Wells Fargo
Wells Fargo notes that shares of GeneDx (WGS) are trading lower after a short report was published this morning by Grizzly Research, adding ...
BTIG says GeneDx short report creates buying opportunity
BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...